STOCK TITAN

[144] Mirum Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) filed a Form 144 reporting the proposed sale of 40,000 common shares acquired by stock option exercise on 08/11/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,480,000 based on the filing and the company has 50,237,647 shares outstanding as shown.

The filing also records a prior sale during the past three months: Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040. The filer certifies they have no undisclosed material adverse information and notes the securities were paid for in cash at acquisition.

Mirum Pharmaceuticals, Inc. (MIRM) ha depositato un Form 144 segnalando la proposta vendita di 40,000 azioni ordinarie acquisite mediante esercizio di opzioni su azioni il 08/11/2025. La vendita sarà eseguita tramite Morgan Stanley Smith Barney LLC con un valore di mercato complessivo di $2,480,000 secondo il deposito, e la società risulta avere 50,237,647 azioni in circolazione, come indicato.

Il deposito riporta anche una vendita precedente negli ultimi tre mesi: Christopher Peetz ha venduto 40,000 azioni il 08/07/2025 per $2,210,040. Il dichiarante certifica di non possedere informazioni materiali sfavorevoli non divulgate e specifica che i titoli sono stati pagati in contanti al momento dell'acquisizione.

Mirum Pharmaceuticals, Inc. (MIRM) presentó un Form 144 informando la propuesta de venta de 40,000 acciones ordinarias adquiridas mediante ejercicio de opciones sobre acciones el 08/11/2025. La venta se realizará a través de Morgan Stanley Smith Barney LLC con un valor de mercado agregado de $2,480,000 según la presentación, y la compañía tiene 50,237,647 acciones en circulación, como se indica.

La presentación también registra una venta previa durante los últimos tres meses: Christopher Peetz vendió 40,000 acciones el 08/07/2025 por $2,210,040. El declarante certifica que no posee información adversa material no divulgada y señala que los valores fueron pagados en efectivo en el momento de la adquisición.

Mirum Pharmaceuticals, Inc. (MIRM)Form 144를 제출하여 08/11/2025주식매수선택권 행사로 취득한 40,000 보통주의 매도를 제안했다고 보고했습니다. 매도는 Morgan Stanley Smith Barney LLC를 통해 실행될 예정이며, 제출서에 따르면 총 시장가치 $2,480,000이고 회사의 발행주식수는 50,237,647주로 기재되어 있습니다.

해당 제출서에는 지난 3개월 동안의 이전 매도도 기재되어 있습니다: Christopher Peetz08/07/202540,000주$2,210,040에 매도했습니다. 제출자는 공개되지 않은 중대한 불리한 정보가 없음을 인증하며, 취득 시 증권은 현금으로 지급되었다고 명시했습니다.

Mirum Pharmaceuticals, Inc. (MIRM) a déposé un Form 144 signalant la proposition de vente de 40,000 actions ordinaires acquises par exercice d'options sur actions le 08/11/2025. La vente doit être exécutée par Morgan Stanley Smith Barney LLC pour un valeur de marché agrégée de $2,480,000 d'après le dépôt, et la société compte 50,237,647 actions en circulation, comme indiqué.

Le dépôt enregistre également une vente antérieure au cours des trois derniers mois : Christopher Peetz a vendu 40,000 actions le 08/07/2025 pour $2,210,040. Le déclarant certifie qu'il ne dispose d'aucune information défavorable matérielle non divulguée et précise que les titres ont été payés en espèces lors de l'acquisition.

Mirum Pharmaceuticals, Inc. (MIRM) hat ein Form 144 eingereicht, in dem der geplante Verkauf von 40.000 Stammaktien gemeldet wird, die durch Ausübung von Aktienoptionen am 08/11/2025 erworben wurden. Der Verkauf soll über Morgan Stanley Smith Barney LLC ausgeführt werden, mit einem Gesamtmarktwert von $2,480,000 laut Einreichung, und das Unternehmen hat nach Angabe 50,237,647 ausstehende Aktien.

Die Einreichung verzeichnet außerdem einen früheren Verkauf in den letzten drei Monaten: Christopher Peetz verkaufte 40.000 Aktien am 08/07/2025 für $2,210,040. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und weist darauf hin, dass die Wertpapiere bei Erwerb in Bargeld bezahlt wurden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider notice for 40,000 shares (~0.08% of outstanding) from an option exercise; transaction size appears modest relative to company equity.

The Form 144 documents a proposed sale of 40,000 common shares acquired on 08/11/2025 via a stock option exercise, to be brokered by Morgan Stanley Smith Barney. The filing lists an aggregate market value of $2,480,000 and total shares outstanding of 50,237,647. From a capital-markets perspective, this represents a small percentage of the company's float, limiting likely market impact. The disclosure of a prior 40,000-share sale on 08/07/2025 for $2,210,040 provides recent pricing context. The form’s attestation about no undisclosed material information is standard.

TL;DR: Routine insider sale notice; compliance with Rule 144 is documented and the filer affirms no undisclosed material information.

The submission is a standard Rule 144 notice disclosing an insider-related sale following a stock option exercise. It names the executing broker and records a recent related sale by Christopher Peetz. The form includes the required attestation regarding material nonpublic information and notes cash payment at acquisition. From a governance standpoint, the filing satisfies disclosure obligations; no governance irregularities are evident in the document itself.

Mirum Pharmaceuticals, Inc. (MIRM) ha depositato un Form 144 segnalando la proposta vendita di 40,000 azioni ordinarie acquisite mediante esercizio di opzioni su azioni il 08/11/2025. La vendita sarà eseguita tramite Morgan Stanley Smith Barney LLC con un valore di mercato complessivo di $2,480,000 secondo il deposito, e la società risulta avere 50,237,647 azioni in circolazione, come indicato.

Il deposito riporta anche una vendita precedente negli ultimi tre mesi: Christopher Peetz ha venduto 40,000 azioni il 08/07/2025 per $2,210,040. Il dichiarante certifica di non possedere informazioni materiali sfavorevoli non divulgate e specifica che i titoli sono stati pagati in contanti al momento dell'acquisizione.

Mirum Pharmaceuticals, Inc. (MIRM) presentó un Form 144 informando la propuesta de venta de 40,000 acciones ordinarias adquiridas mediante ejercicio de opciones sobre acciones el 08/11/2025. La venta se realizará a través de Morgan Stanley Smith Barney LLC con un valor de mercado agregado de $2,480,000 según la presentación, y la compañía tiene 50,237,647 acciones en circulación, como se indica.

La presentación también registra una venta previa durante los últimos tres meses: Christopher Peetz vendió 40,000 acciones el 08/07/2025 por $2,210,040. El declarante certifica que no posee información adversa material no divulgada y señala que los valores fueron pagados en efectivo en el momento de la adquisición.

Mirum Pharmaceuticals, Inc. (MIRM)Form 144를 제출하여 08/11/2025주식매수선택권 행사로 취득한 40,000 보통주의 매도를 제안했다고 보고했습니다. 매도는 Morgan Stanley Smith Barney LLC를 통해 실행될 예정이며, 제출서에 따르면 총 시장가치 $2,480,000이고 회사의 발행주식수는 50,237,647주로 기재되어 있습니다.

해당 제출서에는 지난 3개월 동안의 이전 매도도 기재되어 있습니다: Christopher Peetz08/07/202540,000주$2,210,040에 매도했습니다. 제출자는 공개되지 않은 중대한 불리한 정보가 없음을 인증하며, 취득 시 증권은 현금으로 지급되었다고 명시했습니다.

Mirum Pharmaceuticals, Inc. (MIRM) a déposé un Form 144 signalant la proposition de vente de 40,000 actions ordinaires acquises par exercice d'options sur actions le 08/11/2025. La vente doit être exécutée par Morgan Stanley Smith Barney LLC pour un valeur de marché agrégée de $2,480,000 d'après le dépôt, et la société compte 50,237,647 actions en circulation, comme indiqué.

Le dépôt enregistre également une vente antérieure au cours des trois derniers mois : Christopher Peetz a vendu 40,000 actions le 08/07/2025 pour $2,210,040. Le déclarant certifie qu'il ne dispose d'aucune information défavorable matérielle non divulguée et précise que les titres ont été payés en espèces lors de l'acquisition.

Mirum Pharmaceuticals, Inc. (MIRM) hat ein Form 144 eingereicht, in dem der geplante Verkauf von 40.000 Stammaktien gemeldet wird, die durch Ausübung von Aktienoptionen am 08/11/2025 erworben wurden. Der Verkauf soll über Morgan Stanley Smith Barney LLC ausgeführt werden, mit einem Gesamtmarktwert von $2,480,000 laut Einreichung, und das Unternehmen hat nach Angabe 50,237,647 ausstehende Aktien.

Die Einreichung verzeichnet außerdem einen früheren Verkauf in den letzten drei Monaten: Christopher Peetz verkaufte 40.000 Aktien am 08/07/2025 für $2,210,040. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und weist darauf hin, dass die Wertpapiere bei Erwerb in Bargeld bezahlt wurden.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Mirum (MIRM) Form 144 report?

The Form 144 reports a proposed sale of 40,000 common shares acquired via a stock option exercise on 08/11/2025, to be sold through Morgan Stanley Smith Barney LLC.

What is the aggregate market value and outstanding share count disclosed?

The filing lists an aggregate market value of $2,480,000 for the shares to be sold and reports 50,237,647 shares outstanding.

Was there any related sale in the past three months for MIRM?

Yes. The filing shows Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040.

How were the acquired shares paid for according to the filing?

The securities acquired on 08/11/2025 were paid for in cash, following a stock option exercise.

Does the filer attest to possession of any undisclosed material information?

Yes. The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Mirum Pharmaceuticals

NASDAQ:MIRM

MIRM Rankings

MIRM Latest News

MIRM Latest SEC Filings

MIRM Stock Data

2.68B
42.26M
1.9%
114.17%
13.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY